- Home
- ROOT vs IRWD Comparison
ROOT vs IRWD Comparison
Compare ROOT & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROOT | IRWD |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.6M | 741.8M |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ROOT | IRWD |
|---|---|---|
| Price | $47.66 | $3.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $97.80 | $4.94 |
| AVG Volume (30 Days) | 357.7K | ★ 2.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.96 | ★ 1400.00 |
| EPS | ★ 2.36 | 0.15 |
| Revenue | ★ $1,517,100,000.00 | $298,276,000.00 |
| Revenue This Year | $11.13 | $57.95 |
| Revenue Next Year | $13.29 | $4.39 |
| P/E Ratio | ★ $19.96 | $21.27 |
| Revenue Growth | ★ 28.95 | 8.88 |
| 52 Week Low | $42.65 | $0.55 |
| 52 Week High | $162.99 | $5.78 |
Technical Indicators
Market Signals| Indicator | ROOT | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 39.93 |
| Support Level | $42.65 | $3.08 |
| Resistance Level | $47.83 | $3.53 |
| Average True Range (ATR) | 2.05 | 0.22 |
| MACD | 0.90 | 0.01 |
| Stochastic Oscillator | 88.58 | 16.85 |
Price Performance
Historical ComparisonAbout ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.